Poseida Therapeutics, Inc.
PSTX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $277,879 | $291,865 | $297,661 | $303,022 |
| - Cash | $49,340 | $30,545 | $53,297 | $44,472 |
| + Debt | $82,727 | $83,653 | $84,561 | $85,423 |
| Enterprise Value | $311,266 | $344,973 | $328,925 | $343,973 |
| Revenue | $71,748 | $25,973 | $28,142 | $24,995 |
| % Growth | 176.2% | -7.7% | 12.6% | – |
| Gross Profit | $71,748 | $24,624 | $26,762 | $20,819 |
| % Margin | 100% | 94.8% | 95.1% | 83.3% |
| EBITDA | $23,892 | -$27,763 | -$20,641 | -$21,644 |
| % Margin | 33.3% | -106.9% | -73.3% | -86.6% |
| Net Income | $20,235 | -$31,371 | -$24,274 | -$23,990 |
| % Margin | 28.2% | -120.8% | -86.3% | -96% |
| EPS Diluted | 0.21 | -0.32 | -0.25 | -0.27 |
| % Growth | 165.6% | -28% | 7.4% | – |
| Operating Cash Flow | -$9,594 | $38,450 | -$15,135 | -$28,744 |
| Capital Expenditures | -$645 | -$1,019 | -$130 | -$309 |
| Free Cash Flow | -$10,239 | $37,431 | -$15,265 | -$29,053 |